Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Novo Nordisk A/S (NVO) – Novo Nordisk A/S Price Today

24H
1W
1M
3M
YTD
1Y
5Y

EU approves Cenrifki as first drug targeting disability progression in secondary progressive multiple sclerosis without relapses

The European Commission has approved Cenrifki (tolebrutinib) by Sanofi for treating secondary progressive multiple sclerosis (SPMS) without relapses, based on positive phase 3 trial results showing it delays disability progression. This is the first ...

Market News
1 hour ago
Sanofi
Bullish
news icon
pluang ai news

EU approves Sanofi's Cenrifki for secondary progressive multiple sclerosis without relapses

The European Commission has approved Sanofi's Cenrifki (tolebrutinib) as the first medicine targeting disability progression in secondary progressive multiple sclerosis (SPMS) without relapses. Approval is based on positive phase 3 clinical trial res...

Market News
1 hour ago
Sanofi
Bullish
news icon
pluang ai news

Signify unveils strategy to boost focus, performance, and shareholder value by 2029.

Signify announced a new strategy at its 2026 Capital Markets Day to become a more focused and better-performing company by 2029. The plan includes prioritizing growth in connected lighting and consumer segments while optimizing less profitable areas....

Market News
1 hour ago
Signify
Bullish
news icon
pluang ai news

CTO confidence in scaling AI drops to 48% in 2026 amid rising integration challenges.

Akkodis' 2026 report reveals CTO confidence in scaling AI has fallen from 82% in 2024 to 48% despite increased AI adoption. The main challenge is no longer access to AI technology but integrating it into enterprise systems and workflows. Innovation h...

Market News
2 hours ago
Akkodis
Neutral
pluang ai news

CTO confidence in scaling AI drops to 48% despite rising investments, highlighting integration challenges.

Akkodis' 2026 study reveals CTO confidence in scaling AI has fallen from 82% in 2024 to 48% in 2026, despite rapid AI adoption and increased investments. The main challenge is not technology but integrating AI into company systems, processes, and dec...

Market News
2 hours ago
Akkodis
Neutral
pluang ai news

Bunzl upgrades 2026 revenue outlook on stronger H1 sales and Australian acquisition

Bunzl PLC raised its revenue forecast for 2026 after reporting better-than-expected sales in the first half of the year, driven by volume growth in North America and inflation in some product categories. The company also completed the acquisition of ...

Market News
4 hours ago
Proactive Investors
Bullish
news icon
pluang ai news

Global onion powder market to reach $2.61B by 2035, growing at 6.2% CAGR driven by food industry demand.

The global onion powder market, valued at approximately $1.34 billion in 2025, is projected to grow to $2.61 billion by 2035 at a 6.2% CAGR. Growth is fueled by rising demand for convenient, shelf-stable natural flavor additives in food processing, s...

Market News
4 hours ago
Custom Market Insights
Bullish
news icon
pluang ai news

Pulsar Helium confirms helium-3 discovery in Minnesota, offering a rare terrestrial source for advanced tech.

Pulsar Helium announced the verified discovery of helium-3 at its Topaz Project in Minnesota, confirmed by a U.S. government lab. This rare isotope is crucial for technologies like quantum computing and is currently valued at about $2,500 per liter. ...

Market News
4 hours ago
GlobeNewsWire
Bullish
news icon
pluang ai news

Omnicom launches Acxiom Fan Graph to unify sports fan data for better marketing insights.

Omnicom introduced Acxiom Fan Graph, a new sports marketing intelligence platform that integrates fan data across media, commerce, and engagement into a single privacy-compliant view. This tool helps brands better understand sports fans, optimize mar...

Others
4 hours ago
PRNewsWire
Bullish
news icon
pluang ai news

Flow Traders unveils Horizon 2030 strategy to become top 24/7 liquidity provider with €1B+ net trading income target.

Flow Traders announced its Horizon 2030 strategy aiming to become the preferred 24/7 liquidity provider by leveraging AI, technology, and expanding across traditional, digital, and tokenized assets. The company set ambitious financial goals for 2030,...

Market News
5 hours ago
GlobeNewsWire
Bullish
news icon
pluang ai news
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

Key Stats

  • Market Cap
    $190.89B
  • Sector
    Health
  • 3M Drawdown
    -12.87%
  • Enterprise Value
    $210.09B
  • Dividend Yield
    4.17%
  • Trading Activity
    48% Buy | 52% Sell
  • Typical Hold Time
    104 days
$45.21
52W Low: $35.29
30 Mar 2026
52W High: $71.7
25 Jul 2025

Novo Nordisk A/S (NVO) is currently valued at a market capitalization of $190.89B, with an enterprise value of $210.09B. Over the past 52 weeks, Novo Nordisk A/S has traded between a low of $35.29 and a high of $71.7, highlighting its annual price range. Over the past three months, Novo Nordisk A/S has recorded a drawdown of -12.87%, reflecting recent price volatility. Novo Nordisk A/S offers a dividend yield of 4.17%, with the most recent dividend of $1.28 paid on 30 Mar 26. On average, investors hold Novo Nordisk A/S for approximately 104 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!